Related Experiment Videos
Rimcazole (BW 234 U) and regional monoamine concentrations in mouse brain
Abstract:
Rimcazole (BW 234 U), a novel agent with antipsychotic potential, was administered i.p. (50 mg/kg) to adult male ICR mice 30 minutes before brain removal. Regional HPLC analysis of central monoamine levels showed no change in the DOPAC/DA ratio for any tissue as compared with values obtained from control saline treated animals. However, the MHPG/NE ratio was increased in the septum, striatum, hypothalamus and thalamus and there was a reciprocal decrease in the 5HIAA/5HT ratio in the septum. The data are consistent with a known lack of rimcazole affinity for dopamine receptors and indicate the involvement of alternate neurotransmitter systems in the actions of this drug.
Insights
Rimcazole, an antipsychotic drug, did not affect dopamine levels in mice. However, it altered norepinephrine and serotonin ratios, suggesting involvement of other neurotransmitter systems in its action.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Rimcazole (BW 234 U) is a novel agent with potential antipsychotic properties.
- Understanding the neurochemical mechanisms of antipsychotic agents is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the effects of rimcazole on central monoamine levels in adult male ICR mice.
- To elucidate the neurotransmitter systems involved in the action of rimcazole.
Main Methods:
- Adult male ICR mice were administered rimcazole (50 mg/kg) intraperitoneally.
- Regional high-performance liquid chromatography (HPLC) analysis was used to measure central monoamine levels in brain tissue 30 minutes after administration.
Main Results:
- No significant changes were observed in the DOPAC/DA ratio in any brain region, consistent with rimcazole's lack of dopamine receptor affinity.
- An increased MHPG/NE ratio was found in the septum, striatum, hypothalamus, and thalamus.
- A reciprocal decrease in the 5HIAA/5HT ratio was observed in the septum.
Conclusions:
- Rimcazole's antipsychotic potential is not mediated through dopamine receptor interactions.
- The drug's effects involve alterations in norepinephrine and serotonin neurotransmission.
- These findings indicate the involvement of alternate neurotransmitter systems in the pharmacological actions of rimcazole.